First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity ---- European Commission grants authorization in adults ...

First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity ---- European Commission grants authorization in adults and children 4 years of age and abo ...

The prevalence of obesity is steadily rising and has huge health and financial implications for society. Weight gain is due to an imbalance between dietary intake and energy expenditure and research ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Hypothalamic obesity (HyOb) is a rare type of obesity caused by damage to the hypothalamus, the brain region that regulates hunger, metabolism, and energy balance. This damage disrupts your body’s ...

In a recent review published in the European Journal of Endocrinology, researchers discussed current research on the relationship between human obesity and inflammation of the hypothalamus. In 2022, ...

Findings showed patients on setmelanotide saw a mean BMI reduction of 16.5% from baseline compared with a 3.3% increase for those on placebo at week 52. Topline data were announced from a phase 3 ...

Metabolic syndrome (MetS) is a multifaceted disorder that impacts approximately 20–25% of the global population. This syndrome encompasses a range of conditions, including obesity, type 2 diabetes ...

Add Futurism (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. The ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was linked to reduction in BMI at 52 weeks compared with placebo for patients with acquired ...